Provided by Tiger Trade Technology Pte. Ltd.

Immatics N.V.

8.93
+0.38004.44%
Post-market: 9.430.5000+5.60%19:56 EDT
Volume:611.32K
Turnover:5.44M
Market Cap:1.22B
PE:-4.88
High:9.05
Open:8.60
Low:8.60
Close:8.55
52wk High:12.41
52wk Low:5.05
Shares:137.00M
Float Shares:70.92M
Volume Ratio:0.87
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8285
EPS(LYR):-1.8903
ROE:-47.80%
ROA:-26.92%
PB:2.62
PE(LYR):-4.72

Loading ...

Goldman Sachs Sticks to Its Buy Rating for Immatics (IMTX)

TIPRANKS
·
Aug 19

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 18

Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate

Benzinga Earnings
·
Aug 18

Germany's Immatics Q2 Revenue Rises but Misses Estimates

Reuters
·
Aug 18

Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss

MT Newswires Live
·
Aug 18

Immatics Q2 FY26 Net Loss Narrows to USD 71.2 Million; Revenue Rises 92.59% to USD 10.4 Million

Reuters
·
Aug 18

Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update

Dow Jones
·
Aug 18

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 17

Immatics N.V. Expected to Post a Loss of 43 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Immatics Files Form 3 for General Counsel, Corporate Secretary James Nelson Pepin

Reuters
·
Jul 30

Immatics to Present PRAME Cell Therapy Anzu-cel Phase 1b Melanoma Data at ESMO 2026

Reuters
·
Jul 17

Immatics NV Flags Availability of New Press Release

Reuters
·
Jul 17

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

GlobeNewswire
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Jun 17

Immatics announces annual general meeting

Reuters
·
Jun 02

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

GlobeNewswire
·
Jun 01

Immatics announces presentation of extended data from Phase 1 trial of IMA401

TIPRANKS
·
Jun 01

Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy

TIPRANKS
·
Jun 01

Immatics presents Phase 1 data for IMA401 MAGEA4/8 bispecific at ASCO 2026, supporting lung cancer combo study with IMA402

Reuters
·
May 31

Immatics posts ASCO presentation on PRAME-targeted TCR-T therapies in synovial sarcoma

Reuters
·
May 31